<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; long-term</title>
	<atom:link href="http://www.tapanray.in/tag/long-term/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Deliver Patient-Perceived Value &#8211; Not Incrementally But In Quantum Measure</title>
		<link>http://www.tapanray.in/deliver-patient-perceived-value-not-incrementally-but-in-quantum-measure/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=deliver-patient-perceived-value-not-incrementally-but-in-quantum-measure</link>
		<comments>http://www.tapanray.in/deliver-patient-perceived-value-not-incrementally-but-in-quantum-measure/#comments</comments>
		<pubDate>Mon, 19 Dec 2022 08:22:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[deliver]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[long-term]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[operational]]></category>
		<category><![CDATA[operations]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[perceived]]></category>
		<category><![CDATA[Quantum]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[strategizing]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[sustainability]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10737</guid>
		<description><![CDATA[Many critical functional areas of most drug companies, such as, marketing, manufacturing, supply chain, medical affairs, human resource, R&#38;D, quality assurance, information technology &#8211; traditionally work in silos. It doesn’t mean, though, that there isn’t any interaction between them. Nevertheless, &#8230; <a href="http://www.tapanray.in/deliver-patient-perceived-value-not-incrementally-but-in-quantum-measure/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/deliver-patient-perceived-value-not-incrementally-but-in-quantum-measure/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Key Drivers And Long-Term Impact of Pharma M&amp;A in India</title>
		<link>http://www.tapanray.in/key-drivers-and-long-term-impact-of-pharma-ma-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=key-drivers-and-long-term-impact-of-pharma-ma-in-india</link>
		<comments>http://www.tapanray.in/key-drivers-and-long-term-impact-of-pharma-ma-in-india/#comments</comments>
		<pubDate>Mon, 21 May 2018 00:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[ANDA]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[entity]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[inbound]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[long-term]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[merged]]></category>
		<category><![CDATA[merger]]></category>
		<category><![CDATA[outbound]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8959</guid>
		<description><![CDATA[Corporate M&#38;A is increasingly considered an integral part of the organization’s growth strategy for value creation, by a large number of pharma companies, across the world. In tandem, it throws open many other doors of opportunities, such as reduction of &#8230; <a href="http://www.tapanray.in/key-drivers-and-long-term-impact-of-pharma-ma-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/key-drivers-and-long-term-impact-of-pharma-ma-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
